Literature DB >> 28447377

Lupus miliaris disseminatus faciei: A resistant case with response to cyclosporine.

Kabir Sardana1, Shikha Chugh2, Rashmi Ranjan2, Nita Khurana2,3.   

Abstract

Lupus miliaris disseminatus faciei (LMDF) is a chronic, inflammatory dermatosis of unknown etiology, characterized by multiple, monomorphic, symmetrical, reddish-brown papules over forehead, cheeks, and eyelids. Histopathology shows perifollicular epitheloid cell granuloma. Though numerous therapies, ranging from cyclines, macrolides, dapsone tranilast, isotretinoin, steroids, and tacrolimus have been tried, the results are inconsistent, except with systemic steroids. One approach is to administer therapies based on the histological findings and the corresponding mode of action of drugs, thus antibiotics and dapsone are effective in the early inflammatory stage while clofazamine can be used in the granulomatous stage of the disease. A case of LMDF, recalcitrant to multiple systemic therapies, who responded dramatically to cyclosporine (50 mg twice daily), which probably was due to the specific effect on TH 1 cell response which mediates cell mediated immunity responsible for granulomatous changes on histology has been reported. This case highlights that LMDF is an independent granulomatous entity (not a variant of rosacea or tuberculosis).
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  cyclosporine; lupus miliaris disseminatus faciei

Mesh:

Substances:

Year:  2017        PMID: 28447377     DOI: 10.1111/dth.12496

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  2 in total

1.  A case of lupus miliaris disseminatus faciei after allogeneic hematopoietic stem cell transplantation.

Authors:  Si Zhang; Xiao-Yang Liu; Lin Cai; Chen Zhou; Jian-Zhong Zhang
Journal:  Chin Med J (Engl)       Date:  2019-09-05       Impact factor: 2.628

2.  Recalcitrant lupus miliaris disseminatus faciei improved by cyclosporine monotherapy.

Authors:  Hyeok-Jin Kwon; Kyung-Deok Park; Dong-Wha Yoo; Jeong-Wan Seo; Ki-Ho Kim; Jung-Ho Yoon
Journal:  JAAD Case Rep       Date:  2022-07-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.